The Latest Breaking News from Pfizer

Pfizer's gene therapy trial for Duchenne muscular dystrophy resulted in a young patient's death from cardiac arrest

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

June S&P 500 E-Mini futures (ESM24) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.73% this morning as mixed earnings and the prospect of higher-for-longer U.S. interest rates weighed on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.

Some 75 per cent of Australians at higher risk of serious illness from COVID-19 do not have a plan to manage the potentially-lethal virus, new research shows.

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.